Trials / Recruiting
RecruitingNCT07038096
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZG006 | ZG006 will be administered as an intravenous (IV) infusion. |
| DRUG | ZG005 | ZG005 will be administered as an intravenous (IV) infusion. |
Timeline
- Start date
- 2025-09-23
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
- First posted
- 2025-06-26
- Last updated
- 2026-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07038096. Inclusion in this directory is not an endorsement.